Tobira Therapeutics' (TBRA) CENTAUR Phase 2b Study Design, Rationale Published in Contemporary Clinical Trials
Tweet Send to a Friend
Tobira Therapeutics, Inc. (NASDAQ: TBRA) today announced that the description of the fully-enrolled CENTAUR Phase 2b clinical trial design ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
